| Year |
Citation |
Score |
| 2019 |
Brewer GJ. Avoiding Alzheimer's disease: The important causative role of divalent copper ingestion. Experimental Biology and Medicine (Maywood, N.J.). 1535370219827907. PMID 30727765 DOI: 10.1177/1535370219827907 |
0.321 |
|
| 2017 |
Brewer GJ. The Copper-2 Hypothesis for Causation of the Current Alzheimer's Disease Epidemic. Chemical Research in Toxicology. PMID 28161940 DOI: 10.1021/Acs.Chemrestox.6B00373 |
0.345 |
|
| 2016 |
Brewer GJ. Correction: Brewer, G.J. Copper-2 Ingestion, Plus Increased Meat Eating Leading to Increased Copper Absorption, Are Major Factors Behind the Current Epidemic of Alzheimer's Disease. Nutrients 2015, 7(12), 10053-10064. Nutrients. 8. PMID 27534724 DOI: 10.3390/Nu8040194 |
0.31 |
|
| 2015 |
Brewer GJ. Copper-2 Ingestion, Plus Increased Meat Eating Leading to Increased Copper Absorption, Are Major Factors Behind the Current Epidemic of Alzheimer's Disease. Nutrients. 7: 10053-64. PMID 26633489 DOI: 10.3390/Nu7125513 |
0.346 |
|
| 2015 |
Brewer GJ. Divalent Copper as a Major Triggering Agent in Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 25854930 DOI: 10.3233/Jad-143123 |
0.344 |
|
| 2015 |
Ventriglia M, Brewer GJ, Simonelli I, Mariani S, Siotto M, Bucossi S, Squitti R. Copper in Alzheimer's Disease: A Meta-Analysis of Serum, Plasma, and Cerebrospinal Fluid Studies Journal of Alzheimer's Disease. 24: 175-185. PMID 21187586 DOI: 10.3233/Jad-2010-101473 |
0.309 |
|
| 2014 |
Brewer GJ. The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease. Journal of Trace Elements in Medicine and Biology : Organ of the Society For Minerals and Trace Elements (Gms). 28: 372-8. PMID 25194954 DOI: 10.1016/J.Jtemb.2014.07.015 |
0.309 |
|
| 2014 |
Brewer GJ. Alzheimer's disease causation by copper toxicity and treatment with zinc. Frontiers in Aging Neuroscience. 6: 92. PMID 24860501 DOI: 10.3389/Fnagi.2014.00092 |
0.354 |
|
| 2014 |
Brewer GJ. Treatment of Wilson's disease: Our patients deserve better Expert Opinion On Orphan Drugs. 2: 1245-1248. DOI: 10.1517/21678707.2014.975207 |
0.311 |
|
| 2013 |
Squitti R, Hoogenraad T, Brewer G, Bush AI, Polimanti R. Copper status in Alzheimer's disease and other neurodegenerative disorders 2013. International Journal of Alzheimer's Disease. 2013: 838274. PMID 24455406 DOI: 10.1155/2013/838274 |
0.33 |
|
| 2013 |
Brewer GJ, Kaur S. Zinc deficiency and zinc therapy efficacy with reduction of serum free copper in Alzheimer's disease. International Journal of Alzheimer's Disease. 2013: 586365. PMID 24224111 DOI: 10.1155/2013/586365 |
0.367 |
|
| 2012 |
Brewer GJ. Copper toxicity in Alzheimer's disease: cognitive loss from ingestion of inorganic copper. Journal of Trace Elements in Medicine and Biology : Organ of the Society For Minerals and Trace Elements (Gms). 26: 89-92. PMID 22673823 DOI: 10.1016/J.Jtemb.2012.04.019 |
0.32 |
|
| 2012 |
Brewer GJ. Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease. Biofactors (Oxford, England). 38: 107-13. PMID 22438177 DOI: 10.1002/Biof.1005 |
0.337 |
|
| 2012 |
Brewer GJ. Metals in the causation and treatment of Wilson's disease and Alzheimer's disease, and copper lowering therapy in medicine Inorganica Chimica Acta. 393: 135-141. DOI: 10.1016/J.Ica.2012.06.014 |
0.375 |
|
| 2011 |
Squitti R, Sparks DL, Hoogenraad TU, Brewer GJ. Copper status in Alzheimer's disease and other neurodegenerative disorders: genetics, mechanisms, neurophysiology, and therapies. International Journal of Alzheimer's Disease. 2011: 903940. PMID 22216415 DOI: 10.4061/2011/903940 |
0.335 |
|
| 2011 |
Brewer GJ. Issues raised involving the copper hypotheses in the causation of Alzheimer's disease. International Journal of Alzheimer's Disease. 2011: 537528. PMID 21922048 DOI: 10.4061/2011/537528 |
0.343 |
|
| 2010 |
Brewer GJ, Kanzer SH, Zimmerman EA, Molho ES, Celmins DF, Heckman SM, Dick R. Subclinical zinc deficiency in Alzheimer's disease and Parkinson's disease. American Journal of Alzheimer's Disease and Other Dementias. 25: 572-5. PMID 20841345 DOI: 10.1177/1533317510382283 |
0.36 |
|
| 2010 |
Quinn JF, Harris CJ, Cobb KE, Domes C, Ralle M, Brewer G, Wadsworth TL. A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 21: 903-14. PMID 20693639 DOI: 10.3233/Jad-2010-100408 |
0.316 |
|
| 2010 |
Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman SM, Dick R. Copper and ceruloplasmin abnormalities in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 25: 490-7. PMID 20631161 DOI: 10.1177/1533317510375083 |
0.366 |
|
| 2010 |
Brewer GJ. Risks of copper and iron toxicity during aging in humans. Chemical Research in Toxicology. 23: 319-26. PMID 19968254 DOI: 10.1021/Tx900338D |
0.338 |
|
| 2009 |
Brewer GJ. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases. Metallomics : Integrated Biometal Science. 1: 199-206. PMID 21305118 DOI: 10.1039/B901614G |
0.381 |
|
| 2009 |
Brewer GJ. The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer's disease. Journal of the American College of Nutrition. 28: 238-42. PMID 20150596 DOI: 10.1080/07315724.2009.10719777 |
0.344 |
|
| 2009 |
Hedera P, Peltier A, Fink JK, Wilcock S, London Z, Brewer GJ. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin II. The denture cream is a primary source of excessive zinc. Neurotoxicology. 30: 996-9. PMID 19732792 DOI: 10.1016/J.Neuro.2009.08.008 |
0.342 |
|
| 2009 |
Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, Kluin KJ, Lorincz MT. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Translational Research : the Journal of Laboratory and Clinical Medicine. 154: 70-7. PMID 19595438 DOI: 10.1016/J.Trsl.2009.05.002 |
0.379 |
|
| 2009 |
Tallaksen-Greene SJ, Janiszewska A, Benton K, Hou G, Dick R, Brewer GJ, Albin RL. Evaluation of tetrathiomolybdate in the R6/2 model of Huntington disease. Neuroscience Letters. 452: 60-2. PMID 19429000 DOI: 10.1016/J.Neulet.2009.01.040 |
0.304 |
|
| 2009 |
Hou G, Dick R, Brewer GJ. Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate. Experimental Biology and Medicine (Maywood, N.J.). 234: 662-5. PMID 19307461 DOI: 10.3181/0811-Rm-319 |
0.302 |
|
| 2009 |
Brewer GJ. The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opinion On Investigational Drugs. 18: 89-97. PMID 19053885 DOI: 10.1517/13543780802621859 |
0.357 |
|
| 2008 |
Hou G, Abrams GD, Dick R, Brewer GJ. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis. Translational Research : the Journal of Laboratory and Clinical Medicine. 152: 239-44. PMID 19010295 DOI: 10.1016/J.Trsl.2008.09.003 |
0.307 |
|
| 2008 |
Brewer GJ. The risks of free copper in the body and the development of useful anticopper drugs. Current Opinion in Clinical Nutrition and Metabolic Care. 11: 727-32. PMID 18827576 DOI: 10.1097/Mco.0B013E328314B678 |
0.309 |
|
| 2008 |
Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J. Tetrathiomolybdate versus trientine in the initial treatment of neurologic Wilson's disease Progress in Neurotherapeutics and Neuropsychopharmacology. 3: 153-165. DOI: 10.1017/S1748232107000043 |
0.337 |
|
| 2007 |
Brewer GJ. A brand new mechanism for copper toxicity. Journal of Hepatology. 47: 621-2. PMID 17697726 DOI: 10.1016/J.Jhep.2007.07.001 |
0.331 |
|
| 2007 |
Hou G, Dick R, Zeng C, Brewer GJ. Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate. Translational Research : the Journal of Laboratory and Clinical Medicine. 149: 260-4. PMID 17466925 DOI: 10.1016/J.Trsl.2006.12.003 |
0.353 |
|
| 2007 |
Brewer GJ. Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Experimental Biology and Medicine (Maywood, N.J.). 232: 323-35. PMID 17259340 DOI: 10.3181/00379727-207-2320323 |
0.337 |
|
| 2006 |
Hou G, Dick R, Zeng C, Brewer GJ. Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models. Translational Research : the Journal of Laboratory and Clinical Medicine. 148: 309-14. PMID 17162252 DOI: 10.1016/J.Trsl.2006.06.005 |
0.35 |
|
| 2006 |
Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Archives of Neurology. 63: 521-7. PMID 16606763 DOI: 10.1001/Archneur.63.4.521 |
0.315 |
|
| 2006 |
Mufti AR, Burstein E, Csomos RA, Graf PC, Wilkinson JC, Dick RD, Challa M, Son JK, Bratton SB, Su GL, Brewer GJ, Jakob U, Duckett CS. XIAP Is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders. Molecular Cell. 21: 775-85. PMID 16543147 DOI: 10.1016/J.Molcel.2006.01.033 |
0.343 |
|
| 2006 |
Brewer GJ. Novel therapeutic approaches to the treatment of Wilson's disease. Expert Opinion On Pharmacotherapy. 7: 317-24. PMID 16448326 DOI: 10.1517/14656566.7.3.317 |
0.322 |
|
| 2005 |
Goodman VL, Brewer GJ, Merajver SD. Control of copper status for cancer therapy. Current Cancer Drug Targets. 5: 543-9. PMID 16305350 DOI: 10.2174/156800905774574066 |
0.348 |
|
| 2005 |
Brewer GJ. Anticopper therapy against cancer and diseases of inflammation and fibrosis. Drug Discovery Today. 10: 1103-9. PMID 16182195 DOI: 10.1016/S1359-6446(05)03541-5 |
0.336 |
|
| 2005 |
Brewer GJ. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. Current Cancer Drug Targets. 5: 195-202. PMID 15892619 DOI: 10.2174/1568009053765807 |
0.305 |
|
| 2005 |
Brewer GJ. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. Cns Drugs. 19: 185-92. PMID 15740174 DOI: 10.2165/00023210-200519030-00001 |
0.361 |
|
| 2004 |
Brewer GJ, Dick R, Ullenbruch MR, Jin H, Phan SH. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. Journal of Inorganic Biochemistry. 98: 2160-7. PMID 15541506 DOI: 10.1016/J.Jinorgbio.2004.10.006 |
0.305 |
|
| 2004 |
Goodman VL, Brewer GJ, Merajver SD. Copper deficiency as an anti-cancer strategy. Endocrine-Related Cancer. 11: 255-63. PMID 15163301 DOI: 10.1677/Erc.0.0110255 |
0.335 |
|
| 2004 |
Carlson MD, Al-Mateen M, Brewer GJ. Atypical childhood Wilson's disease. Pediatric Neurology. 30: 57-60. PMID 14738953 DOI: 10.1016/S0887-8994(03)00422-3 |
0.303 |
|
| 2004 |
Burstein E, Ganesh L, Dick RD, van De Sluis B, Wilkinson JC, Klomp LW, Wijmenga C, Brewer GJ, Nabel GJ, Duckett CS. A novel role for XIAP in copper homeostasis through regulation of MURR1. The Embo Journal. 23: 244-54. PMID 14685266 DOI: 10.1038/Sj.Emboj.7600031 |
0.322 |
|
| 2004 |
Hedera P, Brewer GJ. Myelopolyneuropathy Due to Copper Deficiency or Zinc Excess?—Reply Archives of Neurology. 61: 605. DOI: 10.1001/Archneur.61.4.605-A |
0.32 |
|
| 2003 |
Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. The Journal of Laboratory and Clinical Medicine. 142: 385-90. PMID 14713890 DOI: 10.1016/S0022-2143(03)00157-4 |
0.314 |
|
| 2003 |
Hedera P, Fink JK, Bockenstedt PL, Brewer GJ. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin: further support for existence of a new zinc overload syndrome. Archives of Neurology. 60: 1303-6. PMID 12975299 DOI: 10.1001/Archneur.60.9.1303 |
0.34 |
|
| 2003 |
Brewer GJ. Copper in medicine. Current Opinion in Chemical Biology. 7: 207-12. PMID 12714053 DOI: 10.1016/S1367-5931(03)00018-8 |
0.355 |
|
| 2003 |
Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, Sitterly J, Fink JK. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Archives of Neurology. 60: 379-85. PMID 12633149 DOI: 10.1001/Archneur.60.3.379 |
0.335 |
|
| 2003 |
Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, Phan SH. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. The Journal of Laboratory and Clinical Medicine. 141: 210-6. PMID 12624602 DOI: 10.1067/Mlc.2003.20 |
0.344 |
|
| 2003 |
Brewer GJ. Copper lowering therapy with tetrathiomolybdate produces antiangiogenic, anticancer, antifibrotic, and antiinflammatory effects Seminars in Integrative Medicine. 1: 181-190. DOI: 10.1016/S1543-1150(03)00060-7 |
0.321 |
|
| 2003 |
Brewer GJ. Copper-Lowering Therapy With Tetrathiomolybdate for Cancer and Diseases of Fibrosis and Inflammation Journal of Trace Elements in Experimental Medicine. 16: 191-199. DOI: 10.1002/Jtra.10045 |
0.308 |
|
| 2002 |
Brewer GJ, Merajver SD. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review. Integrative Cancer Therapies. 1: 327-37. PMID 14664727 DOI: 10.1177/1534735402238185 |
0.361 |
|
| 2001 |
Brewer GJ. Zinc acetate for the treatment of Wilson's disease. Expert Opinion On Pharmacotherapy. 2: 1473-7. PMID 11585025 DOI: 10.1517/14656566.2.9.1473 |
0.393 |
|
| 2001 |
Brewer GJ. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Experimental Biology and Medicine (Maywood, N.J.). 226: 665-73. PMID 11444102 DOI: 10.1177/153537020222600712 |
0.344 |
|
| 2001 |
Brewer GJ, Dick RD, Johnson VD, Fink JK, Kluin KJ, Daniels S. Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years. The Journal of Laboratory and Clinical Medicine. 137: 191-8. PMID 11241029 DOI: 10.1067/Mlc.2001.113037 |
0.343 |
|
| 2001 |
Brewer GJ. Commentary: Landmark articles on copper in the field of human health The Journal of Trace Elements in Experimental Medicine. 14: 191-194. DOI: 10.1002/Jtra.1027 |
0.346 |
|
| 2000 |
Brewer GJ. Recognition, diagnosis, and management of Wilson's disease. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 223: 39-46. PMID 10632959 DOI: 10.1046/J.1525-1373.2000.22305.X |
0.35 |
|
| 2000 |
Brewer GJ. Raulin Award Lecture: Wilson's disease therapy with zinc and tetrathiomolybdate Journal of Trace Elements in Experimental Medicine. 13: 51-61. DOI: 10.1002/(Sici)1520-670X(2000)13:1<51::Aid-Jtra7>3.0.Co;2-A |
0.379 |
|
| 1999 |
Brewer GJ, Fink JK, Hedera P. Diagnosis and treatment of Wilson's disease. Seminars in Neurology. 19: 261-70. PMID 12194382 DOI: 10.1055/S-2008-1040842 |
0.346 |
|
| 1999 |
Brewer GJ. Treatment of Wilson's disease with zinc. The Journal of Laboratory and Clinical Medicine. 134: 322-4. PMID 10482318 DOI: 10.1016/S0022-2143(99)90213-5 |
0.316 |
|
| 1999 |
Brewer GJ. The treatment of Wilson's disease. Advances in Experimental Medicine and Biology. 448: 115-26. PMID 10079820 DOI: 10.1007/978-1-4615-4859-1_10 |
0.309 |
|
| 1999 |
Fink JK, Hedera P, Brewer GJ. Hepatolenticular degeneration (Wilson's disease) Neurologist. 5: 171-185. DOI: 10.1097/00127893-199907000-00001 |
0.36 |
|
| 1998 |
Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. The Journal of Laboratory and Clinical Medicine. 132: 264-78. PMID 9794697 DOI: 10.1016/S0022-2143(98)90039-7 |
0.387 |
|
| 1998 |
BREWER G. Zinc and Diseases of Digestive Tract Gastroenterology. 115: 1303-1304. DOI: 10.1016/S0016-5085(98)70116-7 |
0.304 |
|
| 1997 |
Rodman R, Burnstine M, Esmaeli B, Sugar A, Martonyi C, Johnson V, Brewer G. Wilson's disease: Presymptomatic patients and Kayser-Fleischer rings Ophthalmic Genetics. 18: 79-85. PMID 9228244 DOI: 10.3109/13816819709057119 |
0.352 |
|
| 1997 |
Brewer GJ, Johnson V, Kaplan J. Treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function. The Journal of Laboratory and Clinical Medicine. 129: 649-52. PMID 9178732 DOI: 10.1016/S0022-2143(97)90200-6 |
0.377 |
|
| 1997 |
Machen M, Montgomery T, Holland R, Braselton E, Dunstan R, Brewer G, Yuzbasiyan-Gurkan V. Bovine hereditary zinc deficiency: lethal trait A 46. Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc. 8: 219-27. PMID 8744744 DOI: 10.1177/104063879600800212 |
0.348 |
|
| 1996 |
Esmaeli B, Burnstine MA, Martonyi CL, Sugar A, Johnson V, Brewer GJ. Regression of Kayser-Fleischer Rings During Oral Zinc Therapy Cornea. 15: 582???588. DOI: 10.1097/00003226-199611000-00008 |
0.33 |
|
| 1995 |
Henderson LM, Brewer GJ, Dressman JB, Swidan SZ, DuRoss DJ, Adair CH, Barnett JL, Berardi RR. Effect of intragastric pH on the absorption of oral zinc acetate and zinc oxide in young healthy volunteers. Jpen. Journal of Parenteral and Enteral Nutrition. 19: 393-7. PMID 8577018 DOI: 10.1177/0148607195019005393 |
0.313 |
|
| 1995 |
Brewer GJ. Practical recommendations and new therapies for Wilson's disease. Drugs. 50: 240-9. PMID 8521757 DOI: 10.2165/00003495-199550020-00004 |
0.327 |
|
| 1995 |
Brewer GJ. Treatment of the Neurologic Manifestations of Wilson's Disease-Reply Archives of Neurology. 52: 340-340. DOI: 10.1001/Archneur.1995.00540280019008 |
0.319 |
|
| 1994 |
Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin K, Fink JK, Aisen A. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Archives of Neurology. 51: 545-54. PMID 8198464 DOI: 10.1001/Archneur.1994.00540180023009 |
0.345 |
|
| 1994 |
Brewer GJ, Turkay A, Yuzbaziyan-Gurkan V. Development of neurologic symptoms in a patient with asymptomatic Wilson's disease treated with penicillamine. Archives of Neurology. 51: 304-5. PMID 8129644 DOI: 10.1001/Archneur.1994.00540150106026 |
0.331 |
|
| 1993 |
Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. Journal of the American College of Nutrition. 12: 26-30. PMID 8440814 DOI: 10.1080/07315724.1993.10718278 |
0.326 |
|
| 1993 |
Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, Wang Y, Johnson V. Does a vegetarian diet control Wilson's disease? Journal of the American College of Nutrition. 12: 527-30. PMID 8263268 DOI: 10.1080/07315724.1993.10718347 |
0.309 |
|
| 1992 |
Brewer GJ, Schall W, Dick R, Yuzbasiyan-Gurkan V, Thomas M, Padgett G. Use of 64copper measurements to diagnose canine copper toxicosis. Journal of Veterinary Internal Medicine / American College of Veterinary Internal Medicine. 6: 41-3. PMID 1548626 DOI: 10.1111/J.1939-1676.1992.Tb00984.X |
0.345 |
|
| 1992 |
Brewer GJ. Thiomolybdates in the Treatment of Wilson's Disease-Reply Archives of Neurology. 49: 132-133. DOI: 10.1001/Archneur.1992.00530260032013 |
0.308 |
|
| 1991 |
Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, Tankanow R, Young AB, Kluin KJ. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Archives of Neurology. 48: 42-7. PMID 1986725 DOI: 10.1001/Archneur.1991.00530130050019 |
0.346 |
|
| 1991 |
Kollros PR, Dick RD, Brewer GJ. Correction of cerebrospinal fluid copper in Menkes kinky hair disease. Pediatric Neurology. 7: 305-7. PMID 1930426 DOI: 10.1016/0887-8994(91)90052-M |
0.332 |
|
| 1990 |
Brewer GJ, Yuzbasiyan-Gurkan V, Lee DY. Use of zinc-copper metabolic interactions in the treatment of Wilson's disease. Journal of the American College of Nutrition. 9: 487-91. PMID 2258535 DOI: 10.1080/07315724.1990.10720405 |
0.385 |
|
| 1989 |
Yuzbasiyan-Gurkan VA, Brewer GJ, Vander AJ, Guenther MJ, Prasad AS. Net renal tubular reabsorption of zinc in healthy man and impaired handling in sickle cell anemia. American Journal of Hematology. 31: 87-90. PMID 2735321 DOI: 10.1002/Ajh.2830310203 |
0.317 |
|
| 1989 |
Yuzbasiyan-Gurkan V, Brewer GJ. The therapeutic use of zinc in macular degeneration. Archives of Ophthalmology (Chicago, Ill. : 1960). 107: 1723-4. PMID 2627236 DOI: 10.1001/Archopht.1989.01070020805004 |
0.344 |
|
| 1989 |
Brewer GJ, Yuzbasiyan-Gurkan V. Deterioration of Wilson's Disease Following the Start of Penicillamine Therapy-Reply Archives of Neurology. 46: 360-361. DOI: 10.1001/Archneur.1989.00520400014008 |
0.303 |
|
| 1988 |
Prasad AS, Meftah S, Abdallah J, Kaplan J, Brewer GJ, Bach JF, Dardenne M. Serum thymulin in human zinc deficiency. The Journal of Clinical Investigation. 82: 1202-10. PMID 3262625 DOI: 10.1172/Jci113717 |
0.338 |
|
| 1987 |
Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Archives of Neurology. 44: 490-3. PMID 3579660 DOI: 10.1001/Archneur.1987.00520170020016 |
0.313 |
|
| 1987 |
Brewer GJ, Hill G, Prasad A, Dick R. The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine and plasma copper. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 184: 446-55. PMID 3562454 DOI: 10.3181/00379727-184-42499 |
0.358 |
|
| 1987 |
Brewer GJ, Hill GM, Dick RD, Nostrant TT, Sams JS, Wells JJ, Prasad AS. Treatment of Wilson's disease with zinc: III. Prevention of reaccumulation of hepatic copper. Journal of Laboratory and Clinical Medicine. 109: 526-531. DOI: 10.5555/Uri:Pii:0022214387901351 |
0.357 |
|
| 1986 |
Hill GM, Brewer GJ, Juni JE, Prasad AS, Dick RD. Treatment of Wilson's disease with zinc. II. Validation of oral 64copper with copper balance. The American Journal of the Medical Sciences. 292: 344-9. PMID 3799705 DOI: 10.1097/00000441-198612000-00002 |
0.392 |
|
| 1985 |
Brewer GJ, Hill GM, Dick RD, Prasad AS, Cossack ZT. Interactions of trace elements: clinical significance. Journal of the American College of Nutrition. 4: 33-8. PMID 3886759 DOI: 10.1080/07315724.1985.10720064 |
0.382 |
|
| 1985 |
Tapazoglou E, Prasad AS, Hill G, Brewer GJ, Kaplan J. Decreased natural killer cell activity in patients with zinc deficiency with sickle cell disease. Journal of Laboratory and Clinical Medicine. 105: 19-22. DOI: 10.5555/Uri:Pii:0022214385900836 |
0.355 |
|
| 1984 |
Brewer GJ, Hill GM, Prasad AS, Rabbani P. Zinc treatment of Wilson's disease. Annals of Internal Medicine. 101: 144-5. PMID 6732083 DOI: 10.7326/0003-4819-101-1-144_3 |
0.317 |
|
| 1984 |
Hill GM, Brewer GJ, Hogikyan ND, Stellini MA. The effect of depot parenteral zinc on copper metabolism in the rat. The Journal of Nutrition. 114: 2283-91. PMID 6502272 DOI: 10.1093/Jn/114.12.2283 |
0.335 |
|
| 1983 |
Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson's disease. Annals of Internal Medicine. 99: 314-9. PMID 6614680 DOI: 10.7326/0003-4819-99-3-314 |
0.367 |
|
| 1981 |
Brewer G. Zinc supplementation treatment of growth retardation and hypogonadism in sickle cell patients. American Journal of Hematology. 10: 195-198. PMID 7234864 DOI: 10.1002/Ajh.2830100211 |
0.308 |
|
| 1978 |
Prasad AS, Brewer GJ, Schoomaker EB, Rabbani P. Hypocupremia induced by zinc therapy in adults. Jama. 240: 2166-8. PMID 359844 DOI: 10.1001/Jama.1978.03290200044019 |
0.663 |
|
| 1977 |
Moore LG, Brewer GJ, Oelshlegel FJ, Brewer LF, Schoomaker EB. Pharmacologic stimulation of erythrocyte 2,3-diphosphoglycerate production in vivo. The Journal of Pharmacology and Experimental Therapeutics. 203: 722-8. PMID 925965 |
0.612 |
|
| 1977 |
Kruckeberg WC, Oelshlegel FJ, Shore SH, Smouse PE, Brewer GJ. The effects of zinc on the morphology of sickle red blood cell ghosts as observed by scanning electron microscopy. Research in Experimental Medicine. Zeitschrift FüR Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie. 170: 149-59. PMID 882712 DOI: 10.1007/Bf01851386 |
0.312 |
|
| 1977 |
Brewer GJ, Schoomaker EB, Leichtman DA, Kruckeberg WC, Brewer LF, Meyers N. The use of pharmacological doses of zinc in the treatment of sickle cell anemia. Progress in Clinical and Biological Research. 14: 241-58. PMID 605140 |
0.601 |
|
| 1977 |
Buchwald D, Argyres S, Easterling RE, Oelshlegel FJ, Brewer GJ, Schoomaker EB, Abbrecht PH, Williams GW, Weller JM. Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients. Nephron. 18: 232-8. PMID 323739 DOI: 10.1159/000180834 |
0.639 |
|
| 1976 |
Schoomaker EB, Brewer GJ, Oelshlegel FJ. Zinc in the treatment of homozygous sickle cell anemia: studies in an animal model. American Journal of Hematology. 1: 45-57. PMID 984036 |
0.639 |
|
| 1976 |
Prasad AS, Ortega J, Brewer GJ, Oberleas D, Schoomaker EB. Trace elements in sickle cell disease. Jama. 235: 2396-8. PMID 946645 DOI: 10.1001/Jama.1976.03260480016021 |
0.652 |
|
| 1976 |
Gilroy TE, Brewer GJ, Oelshlegel FJ, Meyers N, Schoomaker EB. The effect of epinephrine on the in vivo concentration of erythrocyte glycolytic intermediates. Proceedings of the Society For Experimental Biology and Medicine. Society For Experimental Biology and Medicine (New York, N.Y.). 153: 429-35. PMID 13406 DOI: 10.3181/00379727-153-39562 |
0.638 |
|
| 1975 |
Prasad AS, Schoomaker EB, Ortega J, Brewer GJ, Oberleas D, Oelshlegel FJ. Zinc deficiency in sickle cell disease. Clinical Chemistry. 21: 582-7. PMID 1116294 DOI: 10.1093/Clinchem/21.4.582 |
0.669 |
|
| 1974 |
Dash S, Brewer GJ, Oelshlegel FJ. Effect of zinc on haemoglobin binding by red blood cell membranes Nature. 250: 251-252. PMID 4851717 DOI: 10.1038/250251A0 |
0.314 |
|
| 1974 |
Brewer GJ, Oelshlegel FJ. Antisickling effects of zinc. Biochemical and Biophysical Research Communications. 58: 854-61. PMID 4836278 DOI: 10.1016/S0006-291X(74)80495-X |
0.313 |
|
| 1974 |
Oelshlegel FJ, Brewer GJ, Knutsen C, Prasad AS, Schoomaker EB. Studies on the interaction of zinc with human hemoglobin. Archives of Biochemistry and Biophysics. 163: 742-8. PMID 4415957 DOI: 10.1016/0003-9861(74)90536-0 |
0.631 |
|
| 1973 |
Oelshlegel FJ, Brewer GJ, Prasad AS, Knutsen C, Schoomaker EB. Effect of zinc on increasing oxygen affinity of sickle and normal red blood cells. Biochemical and Biophysical Research Communications. 53: 560-6. PMID 4716987 DOI: 10.1016/0006-291X(73)90698-0 |
0.671 |
|
| 1972 |
Brewer GJ, Oelshlegel FJ, Schoomaker EB, Knutsen CA. Potential effects of hemoglobin concentration on red cell metabolism together with observations on red cell metabolic differences between men and women. Advances in Experimental Medicine and Biology. 28: 99-119. PMID 5085189 DOI: 10.1007/978-1-4684-3222-0_7 |
0.626 |
|
| 1972 |
Moore LG, Brewer GJ, Oelshlegel FJ. Red cell metabolic changes in acute and chronic exposure to high altitude Advances in Experimental Medicine and Biology. 28: 397-413. PMID 5085178 DOI: 10.1007/978-1-4684-3222-0_31 |
0.307 |
|
| 1972 |
Brewer GJ, Oelshlegel FJ, Schoomaker EB. Intraerythrocytic regulatory mechanisms for control of glycolysis, DPG levels and pH. Chest. 61: Suppl:60S. PMID 5009872 DOI: 10.1378/Chest.61.2_Supplement.60S |
0.593 |
|
| 1972 |
Oelshlegel FJ, Brewer GJ, Penner JA, Schoomaker EB. Enzymatic mechanisms of red cell adaptation to anemia. Advances in Experimental Medicine and Biology. 28: 377-96. PMID 4404411 DOI: 10.1007/978-1-4684-3222-0_30 |
0.649 |
|
| 1971 |
Brewer GJ, Oelshlegel FJ, Schoomaker EB, Faulkner JA. Stimulation of erythrocyte glycolysis by fear and epinephrine injection. The Journal of Laboratory and Clinical Medicine. 78: 837. PMID 5001924 |
0.551 |
|
| 1969 |
Meyers NL, Brewer GJ, Tashian RE. Enzymatic synthesis of carbonic anhydrases by human reticulocytes. Biochimica Et Biophysica Acta. 195: 176-85. PMID 4982422 DOI: 10.1016/0005-2787(69)90614-5 |
0.536 |
|
| 1969 |
Brewer GJ. Genetic and population studies of quantitative levels of adenosine triphosphate in human erythrocytes. Biochemical Genetics. 1: 25-34. PMID 4887293 DOI: 10.1007/Bf00487733 |
0.312 |
|
| 1968 |
Eaton JW, Brewer GJ. The relationship between red cell 2,3-diphosphoglycerate and levels of hemoglobin in the human. Proceedings of the National Academy of Sciences of the United States of America. 61: 756-60. PMID 5246006 DOI: 10.1073/Pnas.61.2.756 |
0.335 |
|
| 1967 |
Brewer GJ, Bowbeer DR, Tashian RE. The electrophoretic phenotypes of red cell phosphoglucomutase, adenylate kinase, and acid phosphatase n the American Negro. Acta Genetica Et Statistica Medica. 17: 97-103. PMID 5633124 |
0.481 |
|
| 1967 |
Arends T, Brewer G, Chagnon N, Gallango ML, Gershowitz H, Layrisse M, Neel J, Shreffler D, Tashian R, Weitkamp L. Intratribal genetic differentiation among the Yanomama Indians of southern Venezuela. Proceedings of the National Academy of Sciences of the United States of America. 57: 1252-9. PMID 5231731 DOI: 10.1073/Pnas.57.5.1252 |
0.504 |
|
| 1967 |
Tashian RE, Brewer GJ, Lehmann H, Davies DA, Rucknagel DL. Further studies on the Xavante Indians. V. Genetic variability in some serum and erythrocyte enzymes, hemoglobin, and the urinary excretion of beta-aminoisobutyric acid. American Journal of Human Genetics. 19: 524-31. PMID 4962437 |
0.482 |
|
| 1967 |
Brewer GJ, Bowbeer DR, Tashian RE. The electrophoretic phenotypes of red cell phosphoghicomutase, adenylate kinase, and acid phosphatase in the american negro Human Heredity. 17: 97-103. DOI: 10.1159/000152056 |
0.486 |
|
| 1966 |
Eaton GM, Brewer GJ, Tashian RE. Hexokinase isozyme patterns of human erythrocytes and leukocytes. Nature. 212: 944-6. PMID 6004585 DOI: 10.1038/212944B0 |
0.553 |
|
| 1966 |
Dern RJ, Brewer GJ, Tashian RE, Shows TB. Hereditary variation of erythrocytic 6-phosphogluconate dehydrogenase. The Journal of Laboratory and Clinical Medicine. 67: 255-64. PMID 5902888 |
0.486 |
|
| 1966 |
Eaton GM, Brewer GJ, Tashian RE. Hexokinase isozyme patterns of human erythrocytes and leucocytes. Nature. 212: 944-6. PMID 4975830 |
0.463 |
|
| 1964 |
SHOWS TB, TASHIAN RE, BREWER GJ, DERN RJ. ERYTHROCYTE GLUCOSE-6-PHOSPHATE DEHYDROGENASE IN CAUCASIANS: NEW INHERITED VARIANT. Science (New York, N.Y.). 145: 1056-7. PMID 14172618 DOI: 10.1126/Science.145.3636.1056 |
0.531 |
|
| Show low-probability matches. |
